Movement disorders of the mouth: a review of the common phenomenologies.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE

Original Publication: Berlin ; New York, Springer-Verlag

Dyskinesias* ; Dystonic Disorders* ; Movement Disorders*/diagnosis ; Movement Disorders*/therapy; Humans ; Mouth

Movement disorders of the mouth encompass a spectrum of hyperactive movements involving the muscles of the orofacial complex. They are rare conditions and are described in the literature primarily in case reports originating from neurologists, psychiatrists, and the dental community. The focus of this review is to provide a phenomenological description of different oral motor disorders including oromandibular dystonia, orofacial dyskinesia and orolingual tremor, and to offer management strategies for optimal treatment based on the current literature. A literature search of full text studies using PubMed/Medline and Cochrane library combined with a manual search of the reference lists was conducted until June 2021. Results from this search included meta-analyses, systematic reviews, reviews, clinical studies, case series, and case reports published by neurologists, psychiatrists, dentists and oral and maxillofacial surgeons. Data garnered from these sources were used to provide an overview of most commonly encountered movement disorders of the mouth, aiding physicians in recognizing these rare conditions and in initiating appropriate therapy.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)

Albanese A, Bhatia K, Bressman SB et al (2013) Phenomenology and classification of dystonia: a consensus update. Mov Disord 28:863–873. (PMID: 23649720372988010.1002/mds.25475)
Sitburana O, Chen Wu LJ, Sheffield JK et al (2009) Motor overflow and mirror dystonia. Parkinsonism Relat Disord 15:758–761. https://doi.org/10.1016/J.PARKRELDIS.2009.05.003. (PMID: 10.1016/J.PARKRELDIS.2009.05.00319505838)
Tolosa E, Martí MJ (1988) Blepharospasm-oromandibular dystonia syndrome (Meige’s syndrome): clinical aspects. Adv Neurol 49:73–84. (PMID: 3278555)
Bakke M, Larsen BM, Dalager T, Moller E (2013) Oromandibular dystonia - Functional and clinical characteristics: a report on 21 cases. Oral Surg Oral Med Oral Pathol Oral Radiol. https://doi.org/10.1016/j.oooo.2012.04.023. (PMID: 10.1016/j.oooo.2012.04.02322999966)
Jankovic J (1988) Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol 49:103–116. (PMID: 3278535)
Møller E, Bakke M, Dalager T, Werdelin LM (2007) Oromandibular dystonia involving the lateral pterygoid muscles: four cases with different complexity. Mov Disord 22:785–790. https://doi.org/10.1002/mds.21304. (PMID: 10.1002/mds.2130417290453)
Maestre-Ferrín L, Burguera JA, Peñarrocha-Diago M, Peñarrocha-Diago M (2010) Oromandibular dystonia: a dental approach. Med Oral Patol Oral Cir Bucal 15:6.
Clark GT, Ram S (2007) Four oral motor disorders: bruxism, dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions. Dent Clin North Am 51:225–243. (PMID: 1718506810.1016/j.cden.2006.09.002)
Lo SE, Gelb M, Frucht SJ (2007) Geste antagonistes in idiopathic lower cranial dystonia. Mov Disord 22:1012–1017. https://doi.org/10.1002/mds.21149. (PMID: 10.1002/mds.2114917575581)
Schramm A, Classen J, Reiners K, Naumann M (2007) Characteristics of sensory trick-like manoeuvres in jaw-opening dystonia. Mov Disord 22:430–433. https://doi.org/10.1002/mds.21354. (PMID: 10.1002/mds.2135417226856)
Balasubramaniam R, Ram S (2008) Orofacial movement disorders. Oral Maxillofac Surg Clin North Am 20:273–85, vii. https://doi.org/10.1016/j.coms.2007.12.010. (PMID: 10.1016/j.coms.2007.12.01018343330)
Singer C, Papapetropoulos S (2006) A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia. Park Relat Disord 12:115–118. https://doi.org/10.1016/j.parkreldis.2005.07.007. (PMID: 10.1016/j.parkreldis.2005.07.007)
Gonzalez-Alegre P (2014) Clinical, etiological, and therapeutic features of jaw-opening and jaw-closing oromandibular dystonias: a decade of experience at a single treatment center. Tremor and Other Hyperkinetic Movements 4:231. (PMID: 24847442401112210.5334/tohm.194)
Sankhla C, Lai EC, Jankovic J (1998) Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry 65:722–728. https://doi.org/10.1136/jnnp.65.5.722. (PMID: 10.1136/jnnp.65.5.72298109452170345)
Balasubramaniam R, Rasmussen J, Carlson LW et al (2008) Oromandibular dystonia revisited: a review and a unique case. J Oral Maxillofac Surg 66:379–386. https://doi.org/10.1016/j.joms.2006.11.028. (PMID: 10.1016/j.joms.2006.11.02818201628)
Papapetropoulos S, Singer C (2006) Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations. Head Face Med 2:47. https://doi.org/10.1186/1746-160x-2-47. (PMID: 10.1186/1746-160x-2-47171564191702536)
Nutt JG, Muenter MD, Aronson A et al (1988) Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3:188–194. https://doi.org/10.1002/mds.870030302. (PMID: 10.1002/mds.8700303023264051)
Cardoso F, Jankovic J (1997) Dystonia and dyskinesia. Psychiatr Clin North Am 20:821–838. https://doi.org/10.1016/S0193-953X(05)70347-6. (PMID: 10.1016/S0193-953X(05)70347-69443352)
Brin MF, Comella CJJ (2004) Dystonia: etiology, clinical features, and treatment. Lippincott Williams & Wilkins, Philadelphia.
Bakke M, Werdelin LM, Dalager T et al (2003) Reduced jaw opening from paradoxical activity of mandibular elevator muscles treated with botulinum toxin. Eur J Neurol 10:695–699. https://doi.org/10.1046/j.1468-1331.2003.00664.x. (PMID: 10.1046/j.1468-1331.2003.00664.x14641515)
Sankhla C, Jankovic J, Duane D (1998) Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 13:150–154. https://doi.org/10.1002/mds.870130128. (PMID: 10.1002/mds.8701301289452341)
Tan EK, Jankovic J (1999) Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up. Neurology 53:2102–2107. https://doi.org/10.1212/wnl.53.9.2102. (PMID: 10.1212/wnl.53.9.210210599789)
Slaim L, Cohen M, Klap P et al (2018) Oromandibular dystonia: demographics and clinical data from 240 patients. J Mov Disord 11:78–81. https://doi.org/10.14802/jmd.17065. (PMID: 10.14802/jmd.17065298607845990905)
Marsden CD (1976) Blepharospasm-oromandibular dystonia syndrome (Brueghel’s syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry 39:1204–1209. https://doi.org/10.1136/jnnp.39.12.1204. (PMID: 10.1136/jnnp.39.12.12041011031492566)
Warner T, Camfield L, Marsden CD et al (2000) A prevalence study of primary dystonia in eight European countries. J Neurol 247:787–792. https://doi.org/10.1007/s004150070094. (PMID: 10.1007/s004150070094)
Blanchet PJ, Rompré PH, Lavigne GJ, Lamarche C (2005) Oral dyskinesia: a clinical overview. Int J Prosthodont 18:10–19. (PMID: 15754887)
Lee KH (2007) Oromandibular dystonia. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 104:491–496. https://doi.org/10.1016/j.tripleo.2007.04.001. (PMID: 10.1016/j.tripleo.2007.04.001)
Scott BL (2000) Evaluation and treatment of dystonia. South Med J 93:746–751. (PMID: 1096350210.1097/00007611-200093080-00001)
Sinclair CF, Gurey LE, Blitzer A (2013) Oromandibular dystonia: Long-term management with botulinum toxin. Laryngoscope 123:3078–3083. (PMID: 2412289710.1002/lary.23265)
Berman BD, Groth CL, Sillau SH et al (2019) Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2019-321794. (PMID: 10.1136/jnnp-2019-32179431848221)
Frucht SJ, Fahn S, Greene PE et al (2001) The natural histoy of embouchure dystonia. Mov Disord 16:899–906. https://doi.org/10.1002/mds.1167. (PMID: 10.1002/mds.116711746620)
Frucht S (1999) French horn embouchure dystonia. Mov Disord 14:171–173. (PMID: 991836810.1002/1531-8257(199901)14:1<171::AID-MDS1034>3.0.CO;2-1)
Scolding NJ, Smith SM, Sturman S et al (1995) Auctioneer’s jaw: a case of occupational oromandibular hemidystonia. Mov Disord 10:508–509. https://doi.org/10.1002/mds.870100418. (PMID: 10.1002/mds.8701004187565835)
Ilic TV, Pötter M, Holler I et al (2005) Praying-induced oromandibular dystonia. Mov Disord 20:385–386. https://doi.org/10.1002/mds.20353. (PMID: 10.1002/mds.2035315580567)
Bonanni L, Thomas A, Scorrano V, Onofrj M (2007) Task-specific lower lip dystonia due to mantra recitation. Mov Disord 22:439–440. (PMID: 1714970510.1002/mds.21268)
Kang SY, Kim H, Ma HI et al (2011) Highly task-specific oromandibular dystonia in a telephone operator. Eur J Neurol 18:e136. (PMID: 2191404610.1111/j.1468-1331.2011.03468.x)
Colosimo C, Suppa A, Fabbrini G et al (2010) Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17:15–21. (PMID: 2059080310.1111/j.1468-1331.2010.03045.x)
Neychev VK, Gross RE, Lehéricy S et al (2011) The functional neuroanatomy of dystonia. Neurobiol Dis 42:185–201. (PMID: 21303695347878210.1016/j.nbd.2011.01.026)
Jinnah HA, Hess EJ (2006) A new twist on the anatomy of dystonia: the basal ganglia and the cerebellum? Neurology 67:1740–1741. (PMID: 1713040210.1212/01.wnl.0000246112.19504.61)
Le Ber I, Clot F, Vercueil L et al (2006) Predominant dystonia with marked cerebellar atrophy: a rare phenotype in familial dystonia. Neurology 67:1769–1773. https://doi.org/10.1212/01.wnl.0000244484.60489.50. (PMID: 10.1212/01.wnl.0000244484.60489.5017130408)
Waddy HM, Fletcher NA, Harding AE, Marsden CD (1991) A genetic study of idiopathic focal dystonias. Ann Neurol 29:320–324. https://doi.org/10.1002/ana.410290315. (PMID: 10.1002/ana.4102903152042948)
Müller J, Wenning GK, Wissel J et al (2002) Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 249:300–304. https://doi.org/10.1007/s004150200009. (PMID: 10.1007/s00415020000911993530)
Godeiro C, Felício AC, Barsottini OGP et al (2008) Clinical features of dystonia in atypical parkinsonism. Arq Neuropsiquiatr 66:800–804. https://doi.org/10.1590/S0004-282X2008000600004. (PMID: 10.1590/S0004-282X2008000600004)
Bader B, Walker RH, Vogel M et al (2010) Tongue protrusion and feeding dystonia: a hallmark of chorea-acanthocytosis. Mov Disord 25:127–129. (PMID: 1993814810.1002/mds.22863)
Samia Y, Yosra C, Foued B et al (2014) Facial cellulitis revealing choreo-acanthocytosis: a case report. Pan Afr Med J. https://doi.org/10.11604/pamj.2014.17.322.4085. (PMID: 10.11604/pamj.2014.17.322.4085253327504198278)
Dulski J, Sołtan W, Schinwelski M et al (2016) Clinical variability of neuroacanthocytosis syndromes—a series of six patients with long follow-up. Clin Neurol Neurosurg 147:78–83. https://doi.org/10.1016/j.clineuro.2016.05.028. (PMID: 10.1016/j.clineuro.2016.05.02827310290)
Ortega MCP, Skármeta NP, Diaz YJ (2016) Management of oromandibular dystonia on a chorea acanthocytosis: a brief review of the literature and a clinical case. Cranio J Craniomandib Pract 34:332–337. https://doi.org/10.1179/2151090315Y.0000000027. (PMID: 10.1179/2151090315Y.0000000027)
Kanjanasut N, Jagota P, Bhidayasiri R (2010) The first case report of neuroacanthocytosis in Thailand: utilization of a peripheral blood smear technique for detecting acanthocytes. Clin Neurol Neurosurg 112:541–543. https://doi.org/10.1016/j.clineuro.2010.03.027. (PMID: 10.1016/j.clineuro.2010.03.02720430518)
Papageorgiou SG, Kontaxis T, Bonakis A, Kalfakis N (2007) Orofacial dystonia related to Sjogren’s syndrome. Clin Rheumatol 26:1779–1781. https://doi.org/10.1007/s10067-006-0519-4. (PMID: 10.1007/s10067-006-0519-417225057)
Jankovic J (1995) Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 18:197–214. (PMID: 863517910.1097/00002826-199506000-00001)
Korczyn AD, Inzelberg R (1993) Dystonia. Curr Opin Neurol Neurosurg 6:350–357. (PMID: 8507905)
LA Calne DB (1988) Secondary dystonia. Advances in neurology. Raven Press, New York, pp 9–33.
van Pelt-Sprangers MJM, Geijteman ECT, Alsma J et al (2015) Oromandibular dystonia: a serious side effect of capecitabine. BMC Cancer. https://doi.org/10.1186/s12885-015-1132-1. (PMID: 10.1186/s12885-015-1132-1258509564358849)
Ngeow JYY, Prakash KM, Chowbay B et al (2008) Capecitabine-induced oromandibular dystonia: a case report and literature review. Acta Oncol (Madr) 47:1161–1165. (PMID: 10.1080/02841860701721785)
Tan EK, Chan LL, Wong MC (2003) Levodopa-induced oromandibular dystonia in progressive supranuclear palsy. Clin Neurol Neurosurg 105:132–134. https://doi.org/10.1016/S0303-8467(02)00128-2. (PMID: 10.1016/S0303-8467(02)00128-212691807)
Barclay CL, Lang AE (1997) Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 62:352–356. https://doi.org/10.1136/jnnp.62.4.352. (PMID: 10.1136/jnnp.62.4.35291204471074090)
Defazio G, Lamberti P, Lepore V et al (1989) Facial dystonia: clinical features, prognosis and pharmacology in 31 patients. Ital J Neurol Sci 10:553–560. https://doi.org/10.1007/BF02333790. (PMID: 10.1007/BF023337902515166)
Miyaoka T, Miura S, Seno H et al (2003) Jaw-opening dystonia (Brueghel’s syndrome) associated with cavum septi pellucidi and Verga’s ventricle—a case report. Eur J Neurol 10:727–729. (PMID: 1464152010.1046/j.1468-1331.2003.00668.x)
Kulisevsky J, Marti MJ, Ferrer I, Tolosa E (1988) Meige syndrome: neuropathology of a case. Mov Disord 3:170–175. https://doi.org/10.1002/mds.870030209. (PMID: 10.1002/mds.8700302093221903)
Jankovic J, Patel SC (1983) Blepharospasm associated with brainstem lesions. Neurology 33:1237–1240. https://doi.org/10.1212/wnl.33.9.1237. (PMID: 10.1212/wnl.33.9.12376684264)
Gibb WRG, Lees AJ, Marsden CD (1988) Pathological report of four patients presenting with cranial dystonias. Mov Disord 3:211–221. https://doi.org/10.1002/mds.870030305. (PMID: 10.1002/mds.8700303053193961)
Jaw‐opening dystonia presumably caused by a pontine lesion - Dietrichs - 2000 - Movement Disorders - Wiley Online Library. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/1531-8257(200009)15:5%3C1026::AID-MDS1046%3E3.0.CO;2-4 . Accessed 2 Jun 2021.
Pittock SJ, Parisi JE, McKeon A et al (2010) Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 67:1109–1115. https://doi.org/10.1001/archneurol.2010.209. (PMID: 10.1001/archneurol.2010.20920837856)
Bekircan-Kurt CE, Temucin ÇM, Elibol B, Saka E (2013) “Jaw clenching” in anti-Ri—antibody-associated paraneoplastic syndrome. Park Relat Disord 19:132–133. (PMID: 10.1016/j.parkreldis.2012.05.013)
Chung SJ, Hong JY, Lee JE et al (2013) Dental implants-induced task-specific oromandibular dystonia. Eur J Neurol. https://doi.org/10.1111/ene.12124. (PMID: 10.1111/ene.1212424330132)
Thorburn DN, Lee KH (2009) Oromandibular dystonia following dental treatment: case reports and discussion. N Z Dent J 105:18–21. (PMID: 19418679)
Schrag A, Bhatia KP, Quinn NP, Marsden CD (1999) Atypical and typical cranial dystonia following dental procedures. Mov Disord 14:492–496. https://doi.org/10.1002/1531-8257(199905)14:3%3c492::AID-MDS1018%3e3.0.CO;2-4. (PMID: 10.1002/1531-8257(199905)14:3<492::AID-MDS1018>3.0.CO;2-410348476)
Termsarasab P (2019) Chorea. Contin Lifelong Learn Neurol 25:1001–1035. (PMID: 10.1212/CON.0000000000000763)
Machado A, Chien HF, Deguti MM et al (2006) Neurological manifestations in Wilson’s disease: report of 119 cases. Mov Disord 21:2192–2196. https://doi.org/10.1002/mds.21170. (PMID: 10.1002/mds.2117017078070)
Woo KA, Lee JY, Jeon B (2019) Familial spinocerebellar ataxia type 2 parkinsonism presenting as intractable oromandibular dystonia. Tremor Other Hyperkinet Mov 9:1–3.
Markovic V, Dragasevic-Miskovic NT, Stankovic I et al (2016) Dystonia in patients with spinocerebellar ataxia type 2. Mov Disord Clin Pract 3:292–295. https://doi.org/10.1002/mdc3.12274. (PMID: 10.1002/mdc3.1227430713920)
Antenora A, Peluso S, Saccà F et al (2014) Jaw-opening oromandibular dystonia associated with spinocerebellar ataxia type 2. Mov Disord Clin Pract 1:121–122. https://doi.org/10.1002/mdc3.12032. (PMID: 10.1002/mdc3.12032303638656183243)
Vale TC, Povoas Barsottini OG, Pedroso JL (2020) Family history as a clue to the diagnosis of orofacial abnormal movements in a 30-year-old man. Park Relat Disord. https://doi.org/10.1016/j.parkreldis.2020.11.006. (PMID: 10.1016/j.parkreldis.2020.11.006)
Ushe M, Perlmutter JS (2012) Oromandibular and lingual dystonia associated with spinocerebellar ataxia type 8. Mov Disord 27:1741–1743. (PMID: 23283653353920810.1002/mds.25295)
Miyashiro A, Sugihara K, Kawarai T et al (2013) Oromandibular dystonia associated with SCA36. Mov Disord 28:558–559. https://doi.org/10.1002/mds.25304. (PMID: 10.1002/mds.2530423390045)
Steinberger D, Topka H, Fischer D, Müller U (1999) GCH1 mutation in a patient with adult-onset oromandibular dystonia. Neurology 52:877–879. https://doi.org/10.1212/wnl.52.4.877. (PMID: 10.1212/wnl.52.4.87710078749)
Dobričić VS, Kresojević ND, Svetel MV et al (2013) Mutation screening of the DYT6/THAP1 gene in Serbian patients with primary dystonia. J Neurol 260:1037–1042. https://doi.org/10.1007/s00415-012-6753-6. (PMID: 10.1007/s00415-012-6753-623180184)
Cheng FB, Wan XH, Feng JC et al (2011) Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China. Eur J Neurol 18:497–503. https://doi.org/10.1111/J.1468-1331.2010.03192.X. (PMID: 10.1111/J.1468-1331.2010.03192.X20825472)
Thongchuam Y, Panyakaew P, Bhidayasiri R (2020) Orofacial dystonia and asssociated bulbar symptoms in multiple system atrophy: a blinded video analysis. J Neurol Sci 417:116992. https://doi.org/10.1016/j.jns.2020.116992. (PMID: 10.1016/j.jns.2020.11699232622521)
Thongchuam Y, Pattamon Panyakaew RB (2019) Oromandibular manifestations in Parkinson’s disease and atypical parkinsonian disorders: a video case-series analysis. Mov Disord Clin Pract 6:S59-60.
Ichiba M, Nakamura M, Kusumoto A et al (2007) Clinical and molecular genetic assessment of a chorea-acanthocytosis pedigree. J Neurol Sci 263:124–132. https://doi.org/10.1016/j.jns.2007.07.011. (PMID: 10.1016/j.jns.2007.07.01117673232)
Hardie RJ, Pullon HW, Harding AE et al (1991) Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 114(Pt 1):13–49. (PMID: 1998879)
Aasly J, Skandsen T, Rø M (1999) Neuroacanthocytosis—the variability of presenting symptoms in two siblings. Acta Neurol Scand 100:322–325. https://doi.org/10.1111/j.1600-0404.1999.tb00404.x. (PMID: 10.1111/j.1600-0404.1999.tb00404.x10536920)
Wilcox RA, Winkler S, Lohmann K, Klein C (2011) Whispering dysphonia in an Australian family (DYT4): a clinical and genetic reappraisal. Mov Disord 26:2404–2408. https://doi.org/10.1002/MDS.23866. (PMID: 10.1002/MDS.2386621956287)
Schneider SA, Aggarwal A, Bhatt M et al (2006) Severe tongue protrusion dystonia. Neurology 67:940–943. https://doi.org/10.1212/01.WNL.0000237446.06971.72. (PMID: 10.1212/01.WNL.0000237446.06971.7217000958)
Tan EK, Jankovic J (2000) Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 68:186–190. https://doi.org/10.1136/jnnp.68.2.186. (PMID: 10.1136/jnnp.68.2.186106447851736782)
Fasano A, Valadas A, Bhatia KP et al (2012) Psychogenic facial movement disorders: clinical features and associated conditions. Mov Disord 27:1544–1551. https://doi.org/10.1002/MDS.25190. (PMID: 10.1002/MDS.25190230331253633239)
Tarsy D, Dengenhardt AZC (2006) Psychogenic facial spasm (the smirk) presenting as hemifacial spasm. In: Hallett M, Fahn S, Jankovic J, Lang AE, Cloninger CRYS (eds) Psychogenic movement disorders. Lippincott Williams & Williams, Philadelphia, pp 341–343.
Jinnah HA, Factor SA (2015) Diagnosis and treatment of dystonia. Neurol Clin 33:77–100. (PMID: 25432724424823710.1016/j.ncl.2014.09.002)
Raja M (1998) Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 19:57–72. https://doi.org/10.2165/00002018-199819010-00005. (PMID: 10.2165/00002018-199819010-000059673858)
Borison RL (1983) Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol. https://doi.org/10.1097/00002826-198300061-00008. (PMID: 10.1097/00002826-198300061-000086133618)
Gagrat D, Hamilton J, Belmaker RH (1978) Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 135:1232–1233. https://doi.org/10.1176/ajp.135.10.1232. (PMID: 10.1176/ajp.135.10.123229498)
Simpson DM, Hallett M, Ashman EJ et al (2016) Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:1818–1826. https://doi.org/10.1212/WNL.0000000000002560. (PMID: 10.1212/WNL.0000000000002560271647164862245)
Jankovic J (2018) An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 147:84–88. https://doi.org/10.1016/j.toxicon.2017.09.003. (PMID: 10.1016/j.toxicon.2017.09.00328888928)
Jankovic J (2017) Botulinum toxin: state of the art. Mov Disord 32:1131–1138. (PMID: 2863936810.1002/mds.27072)
Comella CL (2018) Systematic review of botulinum toxin treatment for oromandibular dystonia. Toxicon 147:96–99. https://doi.org/10.1016/j.toxicon.2018.02.006. (PMID: 10.1016/j.toxicon.2018.02.00629453996)
Yoshida K (2018) Botulinum neurotoxin injection for the treatment of recurrent temporomandibular joint dislocation with and without neurogenic muscular hyperactivity. Toxins (Basel). https://doi.org/10.3390/toxins10050174. (PMID: 10.3390/toxins10050174)
Jankovic J, Schwartz K, Donovan DT (1990) Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 53:633–639. https://doi.org/10.1136/jnnp.53.8.633. (PMID: 10.1136/jnnp.53.8.6332213039488162)
Van Den Bergh P, Francart J, Mourin S et al (1995) Five-year experience in the treatment of focal movement disorders with low-dose dysportTM botulinum toxin. Muscle Nerve 18:720–729. https://doi.org/10.1002/mus.880180708. (PMID: 10.1002/mus.8801807087783762)
Lo SE, Rosengart AJ, Novakovic RL et al (2005) Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients. Neurocrit Care 3:139–145. https://doi.org/10.1385/NCC:3:2:139. (PMID: 10.1385/NCC:3:2:13916174883)
Brin MF, Fahn S, Moskowitz C et al (1987) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2:237–254. https://doi.org/10.1002/mds.870020402. (PMID: 10.1002/mds.8700204023504553)
Ruiz-de-León-Hernández G, Díaz-Sánchez R-M, Torres-Lagares D et al (2018) Botulinum toxin A for patients with orofacial dystonia: prospective, observational, single-centre study. Int J Oral Maxillofac Surg 47:386–391. https://doi.org/10.1016/j.ijom.2017.11.006. (PMID: 10.1016/j.ijom.2017.11.00629208327)
Moscovich M, Chen ZP, Rodriguez R (2015) Successful treatment of open jaw and jaw deviation dystonia with botulinum toxin using a simple intraoral approach. J Clin Neurosci 22:594–596. https://doi.org/10.1016/j.jocn.2014.08.027. (PMID: 10.1016/j.jocn.2014.08.02725541097)
Yoshida K (2018) Computer-aided design/computer-assisted manufacture-derived needle guide for injection of botulinum toxin into the lateral pterygoid muscle in patients with oromandibular dystonia. J Oral Facial Pain Headache 32:e13–e21. https://doi.org/10.11607/ofph.1955. (PMID: 10.11607/ofph.195529694466)
Nastasi L, Mostile G, Nicoletti A et al (2016) Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J Neurol 263:1702–1708. https://doi.org/10.1007/s00415-016-8185-1. (PMID: 10.1007/s00415-016-8185-127278063)
Ramirez-Castaneda J, Jankovic J (2014) Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 90:344–348. https://doi.org/10.1016/j.toxicon.2014.07.009. (PMID: 10.1016/j.toxicon.2014.07.00925130293)
Posada IJ, Ramos A (2011) Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Park Relat Disord 17:570–572. (PMID: 10.1016/j.parkreldis.2011.04.006)
Mendes RA, Upton LG (2009) Management of dystonia of the lateral pterygoid muscle with botulinum toxin A. Br J Oral Maxillofac Surg 47:481–483. https://doi.org/10.1016/j.bjoms.2008.08.010. (PMID: 10.1016/j.bjoms.2008.08.01018829144)
Sakar O, Matur Z, Mumcu Z et al (2018) Multidisciplinary management of a partially edentulous patient with oromandibular dystonia: a clinical report. J Prosthet Dent 120:173–176. https://doi.org/10.1016/j.prosdent.2017.11.011. (PMID: 10.1016/j.prosdent.2017.11.01129429838)
Simpson DM, Blitzer A, Brashear A et al (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurologysymbol. Neurology 70:1699–1706. https://doi.org/10.1212/01.wnl.0000311389.26145.95. (PMID: 10.1212/01.wnl.0000311389.26145.9518458230)
Bhidayasiri R, Cardoso F, Truong DD (2006) Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 13:21–29. (PMID: 1641759410.1111/j.1468-1331.2006.01441.x)
Teive HAG, Klüppel LE, Munhoz RP et al (2012) Distonia oromandibular com abertura da boca secundária à doença de Wilson tratada com toxina botulínica tipo A. Arq Neuropsiquiatr 70:407–409. https://doi.org/10.1590/S0004-282X2012000600005. (PMID: 10.1590/S0004-282X201200060000522699536)
Hermanowicz N, Truong DD (1991) Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 101:1216–1218. https://doi.org/10.1288/00005537-199111000-00010. (PMID: 10.1288/00005537-199111000-000101943423)
Pedemonte C, Pérez Gutiérrez H, González E et al (2015) Use of onabotulinumtoxina in post-traumatic oromandibular dystonia. J Oral Maxillofac Surg 73:152–157. https://doi.org/10.1016/j.joms.2014.07.027. (PMID: 10.1016/j.joms.2014.07.02725315313)
Teemul TA, Patel R, Kanatas A, Carter LM (2016) Management of oromandibular dystonia with botulinum A toxin: a series of cases. Br J Oral Maxillofac Surg 54:1080–1084. https://doi.org/10.1016/j.bjoms.2016.06.028. (PMID: 10.1016/j.bjoms.2016.06.02827776922)
Bakke M, Baram S, Dalager T et al (2019) Oromandibular dystonia, mental distress and oro-facial dysfunction—a follow-up 8–10 years after start of treatment with botulinum toxin. J Oral Rehabil 46:441–449. https://doi.org/10.1111/joor.12768. (PMID: 10.1111/joor.1276830664806)
Dadgardoust PD, Rosales RL, Asuncion RM, Dressler D (2019) Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis. J Neural Transm 126:141–148. https://doi.org/10.1007/s00702-018-1960-7. (PMID: 10.1007/s00702-018-1960-730604200)
Scorr LM, Silver MR, Hanfelt J et al (2018) Pilot single-blind trial of AbobotulinumtoxinA in oromandibular dystonia. Neurotherapeutics 15:452–458. https://doi.org/10.1007/s13311-018-0620-9. (PMID: 10.1007/s13311-018-0620-9295420225935649)
Charous SJ, Comella CL, Fan W (2011) Jaw-opening dystonia: quality of life after botulinum toxin injections. Ear Nose Throat J. https://doi.org/10.1177/014556131109000210. (PMID: 10.1177/01455613110900021021328222)
Karp BI, Alter K (2016) Botulinum toxin treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol 36:84–91. https://doi.org/10.1055/s-0036-1571952. (PMID: 10.1055/s-0036-157195226866500)
Czyz CN, Burns JA, Petrie TP et al (2013) Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2013.02.001. (PMID: 10.1016/j.ajo.2013.02.00123541393)
Hassell TJW, Charles D (2020) Treatment of blepharospasm and oromandibular dystonia with botulinum toxins. Toxins (Basel) 12:269. (PMID: 10.3390/toxins12040269)
Adler CH, Factor SA, Brin M, Sethi KD (2002) Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. Mov Disord 17:158–161. https://doi.org/10.1002/mds.10001. (PMID: 10.1002/mds.1000111835455)
Yoshida K, Kaji R, Kubori T et al (1998) Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord 13:699–705. https://doi.org/10.1002/mds.870130416. (PMID: 10.1002/mds.8701304169686778)
Yoshida K, Kaji R, Shibasaki H, Iizuka T (2002) Factors influencing the therapeutic effect of muscle afferent block for oromandibular dystonia and dyskinesia: implications for their distinct pathophysiology. Int J Oral Maxillofac Surg 31:499–505. https://doi.org/10.1054/ijom.2002.0291. (PMID: 10.1054/ijom.2002.029112418565)
Jankovic J (2013) Medical treatment of dystonia. Mov Disord 28:1001–1012. (PMID: 2389345610.1002/mds.25552)
Jankovic J (2006) Treatment of dystonia. Lancet Neurol 5:864–872. (PMID: 1698773310.1016/S1474-4422(06)70574-9)
Bhidayasiri R, Tarsy D (2006) Treatment of dystonia. Expert Rev Neurother 6:863–886. (PMID: 1678441010.1586/14737175.6.6.863)
Goldman JG, Comella CL (2003) Treatment of dystonia. Clin Neuropharmacol 26:102–108. (PMID: 1267153010.1097/00002826-200303000-00010)
Cloud LJ, Jinnah HA (2010) Treatment strategies for dystonia. Expert Opin Pharmacother 11:5–15. (PMID: 20001425349554810.1517/14656560903426171)
Albanese A, Barnes MP, Bhatia KP et al (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 13:433–444. (PMID: 1672296510.1111/j.1468-1331.2006.01537.x)
Balash Y, Giladi N (2004) Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 11:361–370. (PMID: 1517173110.1111/j.1468-1331.2004.00845.x)
Ikawa M, Yoneda M, Nakagawa H, Kuriyama M (2006) Case of oromandibular dystonia presenting with severe impairment of mouth-opening, and a marked effect by administration of baclofen. Rinsho Shinkeigaku 46:661–663. (PMID: 17260812)
Badillo SPJ, Jamora RDG (2019) Zolpidem for the treatment of dystonia. Front Neurol 10:779. (PMID: 31379728665053710.3389/fneur.2019.00779)
Vazquez-Delgado E, Okeson JP (2004) Treatment of inferior lateral pterygoid muscle dystonia with zolpidem tartrate, botulinum toxin injections, and physical self-regulation procedures: a case report. Cranio 22:325–329. https://doi.org/10.1179/crn.2004.041. (PMID: 10.1179/crn.2004.04115532318)
Miyazaki Y, Sako W, Asanuma K et al (2012) Efficacy of zolpidem for dystonia: a study among different subtypes. Front Neurol APR. https://doi.org/10.3389/fneur.2012.00058. (PMID: 10.3389/fneur.2012.00058)
Waln O, Jankovic J (2013) Zolpidem improves tardive dyskinesia and akathisia. Mov Disord 28:1748–1749. (PMID: 2363702810.1002/mds.25480)
Martinez-Ramirez D, Paz-Gomez V, Rodriguez RL (2015) Response to zolpidem in oromandibular dystonia: a case report. Park Relat Disord 21:154–155. (PMID: 10.1016/j.parkreldis.2014.11.006)
An JY, Kim JS, Kim YI, Lee KS (2008) Successful treatment of the Meige syndrome with oral zolpidem monotherapy. Mov Disord 23:1619–1621. (PMID: 1858147310.1002/mds.22179)
Greene P, Shale H, Fahn S (1988) Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 50:547–556. (PMID: 3400509)
Fasano A, Bove F, Lang AE (2014) The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry 85:759–769. (PMID: 2416704210.1136/jnnp-2013-305532)
Strzelczyk A, Brk K, Oertel WH (2011) Treatment of paroxysmal dyskinesias. Expert Opin Pharmacother 12:63–72. (PMID: 2110857910.1517/14656566.2010.513971)
Jankovic J, Ford J (1983) Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 13:402–411. https://doi.org/10.1002/ana.410130406. (PMID: 10.1002/ana.4101304066838174)
Hanagasi HA, Bilgic B, Gurvit H, Emre M (2004) Clozapine treatment in oromandibular dystonia. Clin Neuropharmacol 27:84–86. https://doi.org/10.1097/00002826-200403000-00007. (PMID: 10.1097/00002826-200403000-0000715252269)
Patti F, Marano P, Nicoletti F et al (1985) Generalized and focal dystonic syndromes: possible therapy with salmon calcitonin. Eur Neurol 24:386–391. https://doi.org/10.1159/000115831. (PMID: 10.1159/0001158314065158)
Nygaard TG, Marsden CD, Fahn S (1991) Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 41:174–181. https://doi.org/10.1212/wnl.41.2_part_1.174. (PMID: 10.1212/wnl.41.2_part_1.1741899474)
Wilder-Smith E, Tan EK, Law HY et al (2003) Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. J Neurol Sci 213:25–28. https://doi.org/10.1016/S0022-510X(03)00129-1. (PMID: 10.1016/S0022-510X(03)00129-112873751)
Charlesworth G, Mohire MD, Schneider SA et al (2013) Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. Neurology 81:1148–1151. https://doi.org/10.1212/WNL.0b013e3182a55fa2. (PMID: 10.1212/WNL.0b013e3182a55fa2239463153795596)
Eftekhari K, Choe CH, Vagefi MR et al (2015) Oral methylphenidate for the treatment of refractory facial dystonias. Ophthal Plast Reconstr Surg 31:e65–e66. https://doi.org/10.1097/IOP.0000000000000079. (PMID: 10.1097/IOP.000000000000007925951177)
Imai N, Ikawa M (2011) Efficacy of aripiprazole in sulpiride-induced tardive oromandibular dystonia. Intern Med 50:635–637. https://doi.org/10.2169/internalmedicine.50.4475. (PMID: 10.2169/internalmedicine.50.447521422693)
Oulis P, Konstantakopoulos G, Nathanailidis E et al (2012) Low-dose aripiprazole in the treatment of selective serotonin reuptake inhibitors-induced orofacial and buccal dystonia. Psychiatry Clin Neurosci 66:462–463. (PMID: 2283467010.1111/j.1440-1819.2012.02363.x)
Park JE, Srivanitchapoom P, Maurer CW et al (2017) Lack of efficacy of levetiracetam in oromandibular and cranial dystonia. Acta Neurol Scand 136:103–108. https://doi.org/10.1111/ane.12701. (PMID: 10.1111/ane.1270127808417)
De Meyer M, Vereecke L, Bottenberg P et al (2020) Oral appliances in the treatment of oromandibular dystonia: a systematic review. Acta Neurol Belg 120:831–836. https://doi.org/10.1007/s13760-020-01404-4. (PMID: 10.1007/s13760-020-01404-432594465)
Yoshida K (2018) Sensory trick splint as a multimodal therapy for oromandibular dystonia. J Prosthodont Res 62:239–244. https://doi.org/10.1016/j.jpor.2017.09.004. (PMID: 10.1016/j.jpor.2017.09.00429126810)
Cooper T, Smith L (2019) Dental appliance therapy in pantothenate kinase-associated neurodegeneration: case report. Spec Care Dent 39:56–58. https://doi.org/10.1111/scd.12337. (PMID: 10.1111/scd.12337)
Yoshida K (2006) Coronoidomy as treatment for trismus due to jaw-closing oromandibular dystonia. Mov Disord 21:1028–1031. https://doi.org/10.1002/mds.20859. (PMID: 10.1002/mds.2085916552755)
Yoshida K (2017) Surgical intervention for oromandibular dystonia-related limited mouth opening: Long-term follow-up. J Cranio-Maxillofacial Surg 45:56–62. https://doi.org/10.1016/j.jcms.2016.10.009. (PMID: 10.1016/j.jcms.2016.10.009)
Houser M, Waltz T (2005) Meige syndrome and pallidal deep brain stimulation. Mov Disord 20:1203–1205. https://doi.org/10.1002/mds.20522. (PMID: 10.1002/mds.2052215954126)
Blomstedt P, Tisch S, Hariz MI (2008) Pallidal deep brain stimulation in the treatment of Meige syndrome. Acta Neurol Scand 118:198–202. (PMID: 1833662410.1111/j.1600-0404.2008.00999.x)
Zhao XM, Zhang JG, Meng FG (2016) Internal pallidum and subthalamic nucleus deep brain stimulation for oromandibular dystonia. Chin Med J (Engl) 129:1619–1620. (PMID: 10.4103/0366-6999.184475)
Ostrem JL, Marks WJ, Volz MM et al (2007) Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 22:1885–1891. https://doi.org/10.1002/mds.21580. (PMID: 10.1002/mds.2158017618522)
Vercueil L, Pollak P, Fraix V et al (2001) Deep brain stimulation in the treatment of severe dystonia. J Neurol 248:695–700. https://doi.org/10.1007/s004150170116. (PMID: 10.1007/s00415017011611569899)
Wang X, Zhang Z, Mao Z, Yu X (2019) Deep brain stimulation for Meige syndrome: a meta-analysis with individual patient data. J Neurol 266:2646–2656. https://doi.org/10.1007/s00415-019-09462-2. (PMID: 10.1007/s00415-019-09462-231302747)
Blanchet PJ, Abdillahi O, Beauvais C et al (2004) Prevalence of spontaneous oral dyskinesia in the elderly: a reappraisal. Mov Disord 19:892–896. https://doi.org/10.1002/mds.20130. (PMID: 10.1002/mds.2013015300653)
Klawans HL, Tanner CM, Goetz CG (1988) Epidemiology and pathophysiology of tardive dyskinesias. Adv Neurol 49:185–197. (PMID: 2894124)
Bassett A, Remick RA, Blasberg B (1986) Tardive dyskinesia: an unrecognized cause of orofacial pain. Oral Surg Oral Med Oral Pathol 61:570–572. https://doi.org/10.1016/0030-4220(86)90095-2. (PMID: 10.1016/0030-4220(86)90095-23459986)
Osborne TE, Grace EG, Schwartz MK (1989) Severe degenerative changes of the temporomandibular joint secondary to the effects of tardive dyskinesia: a literature review and case report. Cranio J Craniomandib Pract 7:58–62.
Sutcher HD, Underwood RB, Beatty RA, Sugar O (1971) Orofacial dyskinesia: a dental dimension. JAMA J Am Med Assoc 216:1459–1463. https://doi.org/10.1001/jama.1971.03180350037008. (PMID: 10.1001/jama.1971.03180350037008)
Levin T, Heresco-Levy U (1999) Risperidone-induced rabbit syndrome: an unusual movement disorder caused by an atypical antipsychotic. Eur Neuropsychopharmacol 9:137–139. https://doi.org/10.1016/S0924-977X(98)00016-9. (PMID: 10.1016/S0924-977X(98)00016-910082239)
Lees AJ (2002) Odd and unusual movement disorders. Neurol Pract 72:i17–i21.
Hull M, Parnes M (2020) Effective treatment of geniospasm: case series and review of the literature. Tremor Other Hyperkinet Mov 10:1–16. https://doi.org/10.5334/TOHM.141. (PMID: 10.5334/TOHM.141)
Hardie RJ, Lees A (1988) Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850–854. https://doi.org/10.1136/jnnp.51.6.850. (PMID: 10.1136/jnnp.51.6.85029002931033159)
Blanchet PJ (2003) Antipsychotic drug-induced movement disorders. Can J Neurol Sci 30:S101–S107. (PMID: 1269148310.1017/S0317167100003309)
Wu JQ, Chen DC, Tan YL et al (2015) Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia. Hum Psychopharmacol 30:57–63. https://doi.org/10.1002/hup.2453. (PMID: 10.1002/hup.245325572310)
Myers DE, Schooler NR, Zullo TG, Levin H (1993) A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia. J Prosthet Dent 69:578–581. https://doi.org/10.1016/0022-3913(93)90285-V. (PMID: 10.1016/0022-3913(93)90285-V8100580)
Girard P, Monette C, Normandeau L et al (2012) Contribution of orodental status to the intensity of orofacial tardive dyskinesia: an interdisciplinary and video-based assessment. J Psychiatr Res 46:684–687. https://doi.org/10.1016/j.jpsychires.2012.02.003. (PMID: 10.1016/j.jpsychires.2012.02.00322386652)
Blanchet PJ, Girard P, Gauthier G et al (2012) Dental prosthetic rehabilitation approach in tardive dyskinesia with edentulism: a case report. Schizophr Res 136:162–163. (PMID: 2179871710.1016/j.schres.2011.07.004)
Sandyk R, Kay SR (1990) Edentulousness and neuroleptic-induced neck and trunk dyskinesia. Funct Neurol 5:361–363. (PMID: 1982665)
Sutcher H, Soderstrom J, Perry R, Das A (1998) Tardive dyskinesia: dental prosthetic therapy. Panminerva Med 40:154–156. (PMID: 9689838)
Katz W, Kaner T, Carrion J, Goldstein GR (2010) The management of a completely edentulous patient with tardive dyskinesia. Int J Prosthodont 23:217–220. (PMID: 20552086)
Caroff SN, Hurford I, Lybrand J, Campbell EC (2011) Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 29:127–148. (PMID: 21172575301885210.1016/j.ncl.2010.10.002)
American Psychiatric Association (2000) Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR., 4th edn. Washington, DC.
Halliday J, Farrington S, Macdonald S et al (2002) Nithsdale schizophrenia surveys 23: movement disorders. 20-Year review. Br J Psychiatry 181:422–427. https://doi.org/10.1192/bjp.181.5.422. (PMID: 10.1192/bjp.181.5.42212411269)
Seshadri A, Wermers ME, Habermann TJ, Singh B (2021) Long-term efficacy and tolerability of adjunctive aripiprazole for major depressive disorder: systematic review and meta-analysis. Prim Care Companion CNS Disord. https://doi.org/10.4088/PCC.20R02799. (PMID: 10.4088/PCC.20R0279934167174)
Gowda GS, Sastry Nagavarapu LS, Reddy Mukku SS, Farooq Ali S (2019) Amisulpride induced oropharyngeal dyskinesia in a patient with schizophrenia: a case report and review of literature. Asian J Psychiatr 41:78–81. (PMID: 2914604510.1016/j.ajp.2017.10.010)
Chadwick D, Reynolds EH, Marsden CD (1976) Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry 39:1210–1218. https://doi.org/10.1136/jnnp.39.12.1210. (PMID: 10.1136/jnnp.39.12.12101011032492567)
Kirschberg GJ (1975) Dyskinesia—an unusual reaction to ethosuximide. Arch Neurol 32:137–138. https://doi.org/10.1001/archneur.1975.00490440087017. (PMID: 10.1001/archneur.1975.00490440087017804894)
Fann WE, Sullivan JL, Richman BW (1976) Dyskinesias associated with tricyclic antidepressants. Br J Psychiatry 128:490–493. https://doi.org/10.1192/bjp.128.5.490. (PMID: 10.1192/bjp.128.5.4901276554)
Vandel P, Bonin B, Leveque E et al (1997) Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 7:207–212. https://doi.org/10.1016/S0924-977X(97)00405-7. (PMID: 10.1016/S0924-977X(97)00405-79213080)
Ellison JM, Stanziani P (1993) SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 54:432–434. (PMID: 8270587)
Leo RJ (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449–454. https://doi.org/10.4088/JCP.v57n1002. (PMID: 10.4088/JCP.v57n10028909330)
Gerber PE, Lynd LD (1998) Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. https://doi.org/10.1345/aph.17302. (PMID: 10.1345/aph.173029640489)
Pastor P, Moitinho E, Elizalde I et al (1996) Reversible oral-facial dyskinesia in a patient receiving ciprofloxacin hydrochloride. J Neurol 243:616–617. (PMID: 886503210.1007/BF00900953)
De Bleecker JL, Vervaet VL, De Sarro A (2004) Reversible orofacial dyskinesia after ofloxacin treatment. Mov Disord 19:731–732. https://doi.org/10.1002/mds.20053. (PMID: 10.1002/mds.2005315197723)
Host BD, Sloan W (2014) Orofacial dyskinesia associated with the use of levofloxacin. Ann Pharmacother 48:142–144. https://doi.org/10.1177/1060028013507050. (PMID: 10.1177/106002801350705024259611)
Mittal SO, MacHado DG, Jabbari B (2012) Orofacial dyskinesia after moxifloxacin treatment-a case with normal hepatorenal function and review of literature. Clin Neuropharmacol 35:292–294. https://doi.org/10.1097/WNF.0b013e31826ba0eb. (PMID: 10.1097/WNF.0b013e31826ba0eb23151468)
Muthane UB, Prasad BNK, Vasanth A, Satishchandra P (2000) Tardive Parkinsonism, orofacial dyskinesia and akathisia following brief exposure to lithium carbonate. J Neurol Sci 176:78–79. (PMID: 1096029910.1016/S0022-510X(00)00306-3)
Haug B, Holzgraefe M (1991) Orofacial and respiratory tardive dyskinesia: potential side effects of 2-dimethylaminoethanol (deanol)? Eur Neurol 31:423–425. https://doi.org/10.1159/000116708. (PMID: 10.1159/0001167081756771)
Klouz A, Zaïem A, Trabelsi S et al (2007) Orofacial dyskinesia associated with tiemonium. Fundam Clin Pharmacol 21:657–658. https://doi.org/10.1111/j.1472-8206.2007.00522.x. (PMID: 10.1111/j.1472-8206.2007.00522.x18034667)
Kane JM (1995) Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FEKD (ed) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 1485–1495.
Woerner MG, Kane JM, Lieberman JA et al (1991) The prevalence of tardive dyskinesia. J Clin Psychopharmacol 11:34–42. (PMID: 167494910.1097/00004714-199102000-00005)
Kane JM, Woerner M, Borenstein M et al (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258. (PMID: 2873613)
Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473–481. https://doi.org/10.1001/archpsyc.1982.04290040069010. (PMID: 10.1001/archpsyc.1982.042900400690106121548)
Woerner MG, Alvir JMJ, Saltz BL et al (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155:1521–1528. https://doi.org/10.1176/ajp.155.11.1521. (PMID: 10.1176/ajp.155.11.15219812112)
Jeste DV (2000) Tardive dyskinesia in older patients. J Clin Psychiatry 61:27–32. (PMID: 10739328)
Miller DD, McEvoy JP, Davis SM et al (2005) Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80:33–43. https://doi.org/10.1016/j.schres.2005.07.034. (PMID: 10.1016/j.schres.2005.07.03416171976)
Vaddadi K, Hakansson K, Clifford J, Waddington J (2006) Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry 18:133–143. (PMID: 1677766710.1080/09540260600583114)
Jeste DV, Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19:303–315. https://doi.org/10.1093/schbul/19.2.303. (PMID: 10.1093/schbul/19.2.3038100643)
Correll CU, Leucht S, Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414–425. (PMID: 1499296310.1176/appi.ajp.161.3.414)
Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835. https://doi.org/10.1176/ajp.151.6.825. (PMID: 10.1176/ajp.151.6.8257514366)
Koller WC (1983) Edentulous orodyskinesia. Ann Neurol 13:97–99. https://doi.org/10.1002/ana.410130121. (PMID: 10.1002/ana.4101301216830172)
Kane JM, Weinhold P, Kinon B et al (1982) Prevalence of abnormal involuntary movements (“spontaneous dyskinesias”) in the normal elderly. Psychopharmacology 77:105–108. https://doi.org/10.1007/BF00431929. (PMID: 10.1007/BF004319296812127)
Barnes TRE, Rossor M, Trauer T (1983) A comparison of purposeless movements in psychiatric patients treated with antipsychotic drugs, and normal individuals. J Neurol Neurosurg Psychiatry 46:540–546. https://doi.org/10.1136/jnnp.46.6.540. (PMID: 10.1136/jnnp.46.6.54061357611027445)
D’Alessandro R, Benassi G, Cristina E et al (1986) The prevalence of lin-al-facial-buccal dyskinesias in the elderly. Neurology 36:1350–1351. https://doi.org/10.1212/wnl.36.10.1350. (PMID: 10.1212/wnl.36.10.13503762941)
Delwaide PJ, Desseilles M (1977) Spontaneous buccolinguofacial dyskinesia in the elderly. Acta Neurol Scand 56:256–262. https://doi.org/10.1111/j.1600-0404.1977.tb01431.x. (PMID: 10.1111/j.1600-0404.1977.tb01431.x906799)
Bourgeois M, Boueilh P, Tignol J (1980) Spontaneous dyskinesia in the elderly and tardive dyskinesia of neuroleptics. A survey among 270 patients (author’s transl). Encephale 6:37–39. (PMID: 6108850)
Blowers AJ, Borison RL, Blowers CM, Bicknell DJ (1981) Abnormal involuntary movements in the elderly. Br J Psychiatry 139:363–364. (PMID: 612001910.1192/S000712500013404X)
Ticehurst SB (1990) Is spontaneous orofacial dyskinesia an artefact due to incomplete drug history? J Geriatr Psychiatry Neurol 3:208–211. https://doi.org/10.1177/089198879000300406. (PMID: 10.1177/0891988790003004061981469)
Klawans HL, Barr A (1982) Prevalence of spontaneous lingual-facial-buccal dyskinesias in the elderly. Neurology 32:558–559. https://doi.org/10.1212/wnl.32.5.558. (PMID: 10.1212/wnl.32.5.5586122190)
Owens DGC, Johnstone EC, Frith CD (1982) Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 39:452–461. https://doi.org/10.1001/archpsyc.1982.04290040052008. (PMID: 10.1001/archpsyc.1982.042900400520086121546)
Dinan TG, Golden T (1990) Orofacial dyskinesia in Down’s syndrome. Br J Psychiatry 157:131–132. https://doi.org/10.1192/bjp.157.1.131. (PMID: 10.1192/bjp.157.1.1312144461)
Miranda B, Mestre TA, Rodrigues D et al (2018) A rare cause of orofacial dyskinesias. Park Relat Disord 50:122–123. (PMID: 10.1016/j.parkreldis.2018.02.002)
Sotaniemi KA (1983) Chorea-acanthocytosis neurological disease with acanthocytosis. Acta Neurol Scand 68:53–56. https://doi.org/10.1111/j.1600-0404.1983.tb04815.x. (PMID: 10.1111/j.1600-0404.1983.tb04815.x6613527)
Gold MM, Shifteh K, Bello JA et al (2006) Chorea-acanthocytosis: a mimicker of Huntington disease case report and review of the literature. Neurologist 12:327–329. https://doi.org/10.1097/01.nrl.0000245817.18773.f4. (PMID: 10.1097/01.nrl.0000245817.18773.f417122731)
Harirchian M, Maghbooli M, Shirani A (2006) A case of choreoacanthocytosis with marked weight loss: impact of orolingual dyskinesia. Neurol India 54:296–297. https://doi.org/10.4103/0028-3886.27158. (PMID: 10.4103/0028-3886.2715816936394)
Ganesamoorthy K, Surendran R, Jamunarani K et al (2017) An interesting case of a movement disorder. J Assoc Physicians India 65:92–94. (PMID: 28462554)
Bohlega S, Al-Jishi A, Dobson-Stone C et al (2003) Chorea-acanthocytosis: clinical and genetic findings in three families from the Arabian peninsula. Mov Disord 18:403–407. https://doi.org/10.1002/mds.10361. (PMID: 10.1002/mds.1036112671946)
Zhu H, Feng XM, Zhao T, Liu JY (2019) Neuroacanthocytosis with unusual clinical features: a case report. Med (United States). https://doi.org/10.1097/MD.0000000000014050. (PMID: 10.1097/MD.00000000000140506943141)
Papandreou A, Schneider RB, Augustine EF et al (2016) Delineation of the movement disorders associated with FOXG1 mutations. Neurology 86:1794–1800. https://doi.org/10.1212/WNL.0000000000002585. (PMID: 10.1212/WNL.0000000000002585270296304862244)
Giardina F, Lanza G, Calì F, Ferri R (2020) Late-onset oro-facial dyskinesia in spinocerebellar ataxia type 2: a case report. BMC Neurol. https://doi.org/10.1186/s12883-020-01739-8. (PMID: 10.1186/s12883-020-01739-8326002887322863)
Degnan AJ, Capek E, Bowman A (2016) Chorea in the older adult: a full blooded answer. J R Coll Physicians Edinb 46:244–246. https://doi.org/10.4997/JRCPE.2016.407. (PMID: 10.4997/JRCPE.2016.40728504778)
Combarros O, Gutierrez A, Pascual J, Berciano J (1990) Oral dyskinesias associated with bilateral thalamocapsular infarction. J Neurol Neurosurg Psychiatry 53:168–169. https://doi.org/10.1136/jnnp.53.2.168. (PMID: 10.1136/jnnp.53.2.1682313305487960)
Cambier J, Masson MDH (1998) Malattie infettive e/o trasmissibili. In: Ambier J, Masson MDH (eds) Neurologia, Italian. Masson, Milan, pp 331–361.
L B (2001) Affezioni Infettive del Sistema Nervoso Centrale. In: Bergamini L, Bergamasco B, Mutani AE (eds) Manuale di Neurologia Clinica. Libreria Cortina, Milano, pp 565–569.
Martinelli P, Rizzo G, Scaglione C, Capellari S (2013) Neurosyphilis orofacial dyskinesia: the candy sign. Mov Disord 28:246–247. https://doi.org/10.1002/mds.25281. (PMID: 10.1002/mds.2528123166011)
Marto JP, Borbinha C, Lampreia T et al (2017) Teaching video neuro images: candy sign. Neurology 88:e35. (PMID: 2811560610.1212/WNL.0000000000003544)
Lenka A, Thota N, Stezin A et al (2017) Orofacial involuntary movements in neurosyphilis: beyond the candy sign. Tremor Other Hyperkinet Mov. https://doi.org/10.7916/D8000DKM. (PMID: 10.7916/D8000DKM)
Kumar H, Jog M (2011) Missing Huntington’s disease for tardive dyskinesia: a preventable error. Can J Neurol Sci 38:762–764. https://doi.org/10.1017/S0317167100012294. (PMID: 10.1017/S031716710001229421856583)
Dash D, Pandey S (2019) Movement disorders associated with neuronal antibodies. Acta Neurol Scand 139:106–117. (PMID: 3033851710.1111/ane.13039)
DE Casey GJ (1986) Tardive dyskinesia: what is the long-term outcome? In: DE Casey GG (ed) Tardive dyskinesia and neuroleptics: from dogma to reason. American Psychiatric Press Inc, Washington, D.C., pp 76–97.
Glazer WM, Morgenstern H, Schooler N et al (1990) Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 157:585–592. https://doi.org/10.1192/bjp.157.4.585. (PMID: 10.1192/bjp.157.4.5851983390)
Glazer WM, Moore DC, Schooler NR et al (1984) Tardive dyskinesia: a discontinuation study. Arch Gen Psychiatry 41:623–627. https://doi.org/10.1001/archpsyc.1984.01790170097011. (PMID: 10.1001/archpsyc.1984.017901700970116145399)
Soares-Weiser K, Fernandez HH (2007) Tardive dyskinesia. Semin Neurol 27:159–169. https://doi.org/10.1055/s-2007-971169. (PMID: 10.1055/s-2007-97116917390261)
Tarsy D, Lungu C, Baldessarini RJ (2011) Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Elsevier, Amsterdam. (PMID: 10.1016/B978-0-444-52014-2.00043-4)
Soares KV, McGrath JJ (1999) The treatment of tardive dyskinesia—a systematic review and meta-analysis. Schizophr Res 39:1–8. https://doi.org/10.1016/s0920-9964(99)00021-3. (PMID: 10.1016/s0920-9964(99)00021-310480663)
Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD (1998) The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 121:2053–2066. https://doi.org/10.1093/brain/121.11.2053. (PMID: 10.1093/brain/121.11.20539827766)
Margolese HC, Chouinard G, Kolivakis TT et al (2005) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 50:703–714. (PMID: 1636346410.1177/070674370505001110)
Mentzel TQ, Van Der Snoek R, Lieverse R et al (2018) Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis. J Clin Psychiatry. https://doi.org/10.4088/JCP.17r1185. (PMID: 10.4088/JCP.17r118530257080)
Lehman AF, Lieberman JA, Dixon LB, et al (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161:1–56.
Egan MF, Apud J, Wyatt RJ (1997) Treatment of tardive dyskinesia. Schizophr Bull 23:583–609. (PMID: 936599710.1093/schbul/23.4.583)
Caroff SN, Davis VG, Miller DD et al (2011) Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 72:295–303. https://doi.org/10.4088/JCP.09m05793yel. (PMID: 10.4088/JCP.09m05793yel20816031)
Bergman H, Soares-Weiser K (2018) Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018.
Bhidayasiri R, Fahn S, Weiner WJ et al (2013) Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 81:463–469. https://doi.org/10.1212/WNL.0b013e31829d86b6. (PMID: 10.1212/WNL.0b013e31829d86b623897874)
Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S (2018) Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci 389:67–75. (PMID: 2945449310.1016/j.jns.2018.02.010)
Hauser RA, Factor SA, Marder SR et al (2017) KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 174:476–484. (PMID: 2832022310.1176/appi.ajp.2017.16091037)
Factor SA, Remington G, Comella CL et al (2017) The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry 78:1344–1350. https://doi.org/10.4088/JCP.17m11777. (PMID: 10.4088/JCP.17m1177729141124)
Anderson KE, Stamler D, Davis MD et al (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 4:595–604. https://doi.org/10.1016/S2215-0366(17)30236-5. (PMID: 10.1016/S2215-0366(17)30236-528668671)
Fernandez HH, Factor SA, Hauser RA et al (2017) Randomized controlled trial of deutetrabenazine for tardive dyskinesia the ARM-TD study. Neurology 88:2003–2010. https://doi.org/10.1212/WNL.0000000000003960. (PMID: 10.1212/WNL.0000000000003960284466465440239)
Fernandez HH, Stamler D, Davis MD et al (2019) Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry 90:1317–1323. https://doi.org/10.1136/jnnp-2018-319918. (PMID: 10.1136/jnnp-2018-31991831296586)
Zhang WF, Tan YL, Zhang XY et al (2011) Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72:615–621. https://doi.org/10.4088/JCP.09m05125yel. (PMID: 10.4088/JCP.09m05125yel20868638)
Bobruff A, Gardos G, Tarsy D et al (1981) Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry 138:189–193. https://doi.org/10.1176/ajp.138.2.189. (PMID: 10.1176/ajp.138.2.1896109454)
Thaker GK, Nguyen JA, Strauss ME et al (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 147:445–451. https://doi.org/10.1176/ajp.147.4.445. (PMID: 10.1176/ajp.147.4.4451969244)
Kenney C, Jankovic J (2006) Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 6:7–17. (PMID: 1646630710.1586/14737175.6.1.7)
Jankovic J, Beach J (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358–362. https://doi.org/10.1212/WNL.48.2.358. (PMID: 10.1212/WNL.48.2.3589040721)
Pappa S, Tsouli S, Apostolou G et al (2010) Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33:271–275. https://doi.org/10.1097/WNF.0b013e3181ffde32. (PMID: 10.1097/WNF.0b013e3181ffde3221121175)
Wolf E, Seppi K, Katzenschlager R et al (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 25:1357–1363. https://doi.org/10.1002/mds.23034. (PMID: 10.1002/mds.2303420198649)
Pajo AT, Espiritu AI, Jamora RDG (2019) Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis. Neurodegener Dis Manag 9:205–215. https://doi.org/10.2217/nmt-2019-0011. (PMID: 10.2217/nmt-2019-001131392922)
Soares-Weiser K, Maayan N, McGrath J (2011) Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd000209.pub2. (PMID: 10.1002/14651858.cd000209.pub2221613844160006)
Neurocrine Biosciences (2017) Ingrezza [package insert]. San Diego.
Auspex, Pharmaceuticals (2017) AUSTEDO [package insert]. North Wales.
Chen JJ, Ondo WG, Dashtipour K, Swope DM (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 34:1487–1504. (PMID: 2274925910.1016/j.clinthera.2012.06.010)
Essali A, Soares-Weiser K, Bergman H, Adams CE (2018) Calcium channel blockers for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018.
Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA (2016) Propranolol therapy for Tardive dyskinesia: a retrospective examination. Parkinsonism Relat Disord 32:124–126. https://doi.org/10.1016/j.parkreldis.2016.09.004. (PMID: 10.1016/j.parkreldis.2016.09.00427622970)
Chatterjee A, Gordon MF, Giladi N, Trosch R (1997) Botulinum toxin in the treatment of tardive dystonia. J Clin Psychopharmacol 17:497–498. (PMID: 940882010.1097/00004714-199712000-00016)
Yasufuku-Takano J, Sakurai M, Kanazawa I, Nagaoka M (1995) Successful treatment of intractable tardivedyskinesia with botulinuim toxin. J Neurol Neurosurg Psychiatry 58:511–512. (PMID: 7738574107345410.1136/jnnp.58.4.511)
Rapaport A, Sadeh M, Stein D et al (2000) Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord 15:352–355. https://doi.org/10.1002/1531-8257(200003)15:2%3c352::AID-MDS1030%3e3.0.CO;2-X. (PMID: 10.1002/1531-8257(200003)15:2<352::AID-MDS1030>3.0.CO;2-X10752596)
Truong DD, Hermanowicz N, Rontal M (1990) Botulinum toxin in treatment of tardive dyskinetic syndrome. J Clin Psychopharmacol 10:438–439. (PMID: 2286715)
van Harten PN, Hovestadt A (2006) Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord 21:1276–1277. https://doi.org/10.1002/mds.20904. (PMID: 10.1002/mds.2090416671083)
Kañovský P, Streitová H, Bares̃ M, Hortová H, (1999) Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect. Mov Disord 14:886–888. https://doi.org/10.1002/1531-8257(199909)14:5%3c886::AID-MDS1034%3e3.0.CO;2-W. (PMID: 10.1002/1531-8257(199909)14:5<886::AID-MDS1034>3.0.CO;2-W10495063)
Slotema CW, van Harten PN, Bruggeman R, Hoek HW (2008) Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuro-Psychopharmacology Biol Psychiatry 32:507–509. https://doi.org/10.1016/j.pnpbp.2007.10.004. (PMID: 10.1016/j.pnpbp.2007.10.004)
Pouclet-Courtemanche H, Rouaud T, Thobois S et al (2016) Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 86:651–659. https://doi.org/10.1212/WNL.0000000000002370. (PMID: 10.1212/WNL.000000000000237026791148)
Farag AM, Mier RW, Correa LP (2016) Utilizing the concept of geste antagoniste for conservative management of oro-mandibular tardive dyskinesia: a case report and mini-review. Cranio - J Craniomandib Pract 34:338–342. https://doi.org/10.1179/2151090315Y.0000000022. (PMID: 10.1179/2151090315Y.0000000022)
Silverdale MA, Schneider SA, Bhatia KP, Lang AE (2008) The spectrum of orolingual tremor—a proposed classification system. Mov Disord 23:159–167. (PMID: 1797332410.1002/mds.21776)
Miles TS, Findley LJ, Rothwell JC (1997) Electrophysiological observations on an unusual, task specific jaw tremor. J Neurol Neurosurg Psychiatry 63:251–254. https://doi.org/10.1136/jnnp.63.2.251. (PMID: 10.1136/jnnp.63.2.25192854682169678)
Jacome DE, Yanez GF (1987) Tremors of the smile. J Neurol Neurosurg Psychiatry 50:489–490. https://doi.org/10.1136/jnnp.50.4.489. (PMID: 10.1136/jnnp.50.4.48935853651031891)
Tarsy D, Ro SI (2006) Unusual position-sensitive jaw tremor responsive to botulinum toxin. Mov Disord 21:277–278. https://doi.org/10.1002/mds.20737. (PMID: 10.1002/mds.2073716211606)
O’Gorman CM, Bower JH, Matsumoto JY et al (2014) When drinking makes the tremor worse: a task-specific orolingual tremor. Mov Disord Clin Pract 1:237–239. https://doi.org/10.1002/mdc3.12041. (PMID: 10.1002/mdc3.12041303638766183252)
Tilikete C, Desestret V (2017) Hypertrophic olivary degeneration and palatal or oculopalatal tremor. Front Neurol 8:302. https://doi.org/10.3389/FNEUR.2017.00302/BIBTEX. (PMID: 10.3389/FNEUR.2017.00302/BIBTEX287065045490180)
Lapresle J, Ben HM (1970) The dentato-olivary pathway. Somatotopic relationship between the dentate nucleus and the contralateral inferior olive. Arch Neurol 22:135–143. https://doi.org/10.1001/ARCHNEUR.1970.00480200041004. (PMID: 10.1001/ARCHNEUR.1970.004802000410044188259)
Deuschl G, Mischke G, Schenck E et al (1990) Symptomatic and essential rhythmic palatal myoclonus. Brain 113(Pt 6):1645–1672. https://doi.org/10.1093/BRAIN/113.6.1645. (PMID: 10.1093/BRAIN/113.6.16452276039)
Wenning GK, Tison F, Ben Shlomo Y et al (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12:133–147. https://doi.org/10.1002/mds.870120203. (PMID: 10.1002/mds.8701202039087971)
Nath U, Ben Shlomo Y, Thomson RG et al (2001) Clinical features of progressive supranuclear palsy (PSP) in the United Kingdom. Neurology 56:A458.
Carpentier A, Selfani K, Huot P (2016) Task-specific oro-lingual tremor following gingival grafting surgery. J Neurol Sci 367:24–25. (PMID: 2742355810.1016/j.jns.2016.05.043)
Valentino P, Labate A, Pirritano D et al (2008) Orolingual tremor as unusual presentation of anti-Hu paraneoplastic syndrome. Mov Disord 23:1791–1792. https://doi.org/10.1002/mds.22205. (PMID: 10.1002/mds.2220518709670)
Acar G, Acar F, Bir LS et al (2010) Vim stimulation in Holmes’ tremor secondary to subarachnoid hemorrhage. Neurol Res 32:992–994. https://doi.org/10.1179/016164110X12714125204272. (PMID: 10.1179/016164110X1271412520427220546686)
Keane JR (1995) Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Neurosurgery 37:520–522. https://doi.org/10.1227/00006123-199509000-00023. (PMID: 10.1227/00006123-199509000-000237501120)
Vilensky JA, Goetz CG, Gilman S (2006) Movement disorders associated with encephalitis lethargica: a video compilation. Mov Disord 21:1–8. (PMID: 1620053810.1002/mds.20722)
Gordon MF, Bressman S, Brin MF et al (1995) Dystonia in a patient with deletion of 18q. Mov Disord 10:496–499. https://doi.org/10.1002/mds.870100415. (PMID: 10.1002/mds.8701004157565832)
White RP, Muqit MMK, Mak I et al (2000) Jaw tremor in mitochondrial disease associated with the A to G 3243 point mutation. J Neurol 247:972–973. (PMID: 1120069410.1007/s004150070058)
Kim HJ, Cho JY, Cho YJ, Hong KS (2009) Levosulpiride-induced resting orolinguai tremor. Mov Disord 24:1700–1701. https://doi.org/10.1002/mds.22578. (PMID: 10.1002/mds.2257819452563)
Louis ED (2001) Essential Tremor. N Engl J Med 345:887–891. https://doi.org/10.1056/NEJMcp010928. (PMID: 10.1056/NEJMcp01092811565522)
Obwegeser AA, Uitti RJ, Turk MF et al (2000) Thalamic stimulation for the treatment of midline tremors in essential tremor patients. Neurology 54:2342–2344. https://doi.org/10.1212/WNL.54.12.2342. (PMID: 10.1212/WNL.54.12.234210881269)
Pulzke JD, Uitti KJ, Obwegeser AA et al (2005) Bilateral thalamic deep brain stimulation: midline tremor control. J Neurol Neurosurg Psychiatry 76:684–690. https://doi.org/10.1136/jnnp.2004.041434. (PMID: 10.1136/jnnp.2004.041434)
Schneider SA, Edwards MJ, Cordivari C et al (2006) Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson’s disease. Mov Disord 21:1722–1724. https://doi.org/10.1002/mds.21019. (PMID: 10.1002/mds.2101916817198)
Gerschlager W, Münchau A, Katzenschlager R et al (2004) Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord 19:788–795. (PMID: 1525493610.1002/mds.20132)
Gonzalez-Alegre P, Kelkar P, Rodnitzky RL (2006) Isolated high-frequency jaw tremor relieved by botulinum toxin injections. Mov Disord 21:1049–1050. https://doi.org/10.1002/mds.20878. (PMID: 10.1002/mds.2087816602105)
Ebersbach G, Tracik F, Wissel J, Poewe W (1997) Tardive jaw tremor. Mov Disord 12:460–462. https://doi.org/10.1002/mds.870120334. (PMID: 10.1002/mds.8701203349159750)

Keywords: Botulinum toxin; Edentulism; Orofacial dyskinesia; Oromandibular dystonia; Tardive dyskinesia

Date Created: 20220729 Date Completed: 20221013 Latest Revision: 20221013

20240104

10.1007/s00415-022-11299-1

35904592